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ABSTRACT Clinically ineffective transplatin [trans-diamminedichloridoplatinum(II)] is used in the studies of the structure-pharma-
cological activity relationship of platinum compounds. In addition, a number of transplatin analogs exhibit promising toxic effects in
several tumor cell lines including those resistant to conventional antitumor cisplatin. Moreover, transplatin-modiﬁed oligonucleotides
havebeenshown to beeffectivemodulators of geneexpression.Owing to these facts andbecauseDNA is also considered themajor
pharmacological target of platinum complexes, interactions between transplatin and DNA are of great interest. We examined, using
biophysical and biochemical methods, the stability of 1,3-GNG intrastrand cross-links (CLs) formed by transplatin in short synthetic
oligodeoxyribonucleotide duplexes and natural double-helical DNA. We have found that transplatin forms in double-helical DNA
1,3-GNG intrastrand CLs, but their stability depends on the sequence context. In some sequences the 1,3-GNG intrastrand CLs
formedby transplatin indouble-helicalDNA readily rearrange into interstrandCLs.On theother hand, inanumber of other sequences
these intrastrand CLs are relatively stable. We show that the stability of 1,3-GNG intrastrand CLs of transplatin correlates with the
extent of conformational distortion and thermodynamic destabilization induced in double-helical DNA by this adduct.
INTRODUCTION
Almost 40 years have elapsed since the accidental discovery
of the anticancer activity of cisplatin (cis-diamminedi-
chloridoplatinum(II)) (Fig. 1 A) (1). Despite its success, cis-
platin has several disadvantages. The drawbacks coupledwith
cisplatin toxicity have been the impetus for the development
of improved platinum drugs. The design of new platinum
drugs with improved antitumor effects depends on under-
standing existing platinum agents with a view toward devel-
oping new modes of attack (2,3). Therefore, it is of great
interest to understand details of the biophysical and bio-
chemical mechanisms underlying the biological efﬁcacy of
the platinum compounds and to deﬁne their structure-phar-
macological relationships. Although a lot of effort has been
devoted to understanding the mechanism of antitumor effects
of cisplatin, not all aspects of themechanism are entirely clear.
Structure-activity studies often use inactive compounds
such as trans-diamminedichloridoplatinum(II) (transplatin,
the geometric isomer of cisplatin) (Fig. 1 A) (4). This com-
pound has been used widely to investigate the mechanism of
action of cisplatin. In this approach, one searches for differ-
ences between active and inactive compounds that may be
responsible for the pharmacological effect. Hence, the clin-
ical inactivity of the trans isomer of cisplatin was considered
for a relatively long time a paradigm for the classical struc-
ture–activity relationships of platinum drugs (5). However, a
series of bifunctional trans-platinum(II) complexes have
been synthesized that show anticancer activity distinct from
cisplatin (sometimes even more efﬁcient than cisplatin itself
and its analogs) and these complexes bind to DNA in a
manner distinctly different from that of cisplatin (6–10).
It is generally accepted that DNA is the primary pharma-
cological target of platinum antitumor drugs, although other
biological targets may also be important in the cisplatin
mechanism (11). Platinum antitumor drugs bind efﬁciently to
DNA forming a variety of adducts that block replication and
transcription and induce cell death (8,12,13). Themechanistic
explanation of transplatin inactivity has been based on the
type of DNA adducts formed by this isomer, as well as on its
chemical reactivity that can render the complex susceptible to
deactivation before its delivery to the tumor site. Notably, a
distinct difference between cisplatin and its trans isomer is
that transplatin is chemically more reactive than cisplatin and
more susceptible to deactivation. Whereas the major adducts
of cisplatin are intrastrand cross-links (CLs) between neigh-
boring purine residues, transplatin-DNA adducts are inter-
strand CLs (;12% in linear DNA) (14) and a relatively large
portion of adducts (50%) remains monofunctional(15).
Transplatin is sterically restricted in the type of intrastrand
CLs it can feasibly produce; that is, it is unable to cross-link
neighboring bases in a DNA strand like cisplatin. It can
crosslink two bases on the same strand only if they are sepa-
rated by at least one intervening base, formingmostly 1,3-GNG
CLs (where G ¼ guanine and N ¼ adenine, cytosine, or
thymine) (14–16). In contradiction to this ﬁnding, it has been
suggested (17,18) that these intrastrand adducts of transplatin
are only stable in single-stranded DNA, whereas they re-
arrange in double-helical DNA into interstrand CLs (17,19). It
has also been suggested (18) that in cells transplatin forms only
a small amount of interstrand adducts and no intrastrand CLs.
The conclusion that intrastrand CLs are not formed in the
reaction between transplatin and double-helical DNA (17,19)
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was drawn on the basis of the ﬁndings that 1,3-GNG intra-
strand CLs readily formed by transplatin in single-stranded
DNA rearrange into interstrand CLs after hybridization of
these platinated single-strands with their complementary
counterparts. However, these studies were only carried out
with a relatively small number of sequence contexts. In ad-
dition, the phenomenon that the linkage isomerization reac-
tion (rearrangement of intrastrand CLs of transplatin into
interstrand adducts) is exclusively triggered by the formation
of a double helix has been proposed as a basis for concept of
the use of transplatin-modiﬁed oligonucleotides to block the
cellular machinery speciﬁcally and irreversibly, i.e., as
modulators of gene expression (19,20). Also interestingly, the
replacement of an ammine ligand(s) in transplatin by a het-
erocyclic ligand(s) results in the distinctively enhanced sta-
bility of the intrastrand CLs in several sequence contexts and
concomitantly in cytotoxicity in tumor cell lines including
those resistant to cisplatin (21–25). Thus, there is an interest in
understanding more deeply the properties of intrastrand CLs
of transplatin and to clarify some discrepancies that appear in
the literature concerning the stability of these adducts and the
frequency of their occurrence in double-helical DNA.
Therefore, we reexamined in this study, using various
biophysical and biochemical methods, the stability of 1,3-
GNG intrastrand CLs in double-helical DNA formed by
transplatin in a number of other sequence contexts than were
those used in previous studies. We have found that the sta-
bility of these intrastrand adducts of transplatin depends on
the sequence context and correlates with the extent of con-
formational distortion and thermodynamic destabilization
induced in double-helical DNA by this adduct.
MATERIALS AND METHODS
Starting materials
Transplatin (Fig. 1A) was obtained fromSigma (Prague, CzechRepublic). The
stock solution of transplatin was prepared at a concentration of 53 104 M
in 10 mM NaClO4 in the dark at 25C. Plasmid pUC19 (2686 bp) was
isolated according to standard procedures. The synthetic oligodeoxy-
ribonucleotides (Fig. 1 B) were purchased from VBC-genomics (Vienna,
Austria) or DNA Technology (Aarhus, Denmark). The purity of the oligo-
nucleotides was veriﬁed by high-pressure liquid chromatography (HPLC) or
gel electrophoresis. Restriction endonucleases and the Klenow fragment
from DNA polymerase I (exonuclease minus, mutated to remove the 39/59
proofreading domain) and T4 polynucleotide kinase were purchased from
New England BioLabs (Beverly, MA). Sequenase 2 was from USB Cor-
poration (Cleveland, OH). Acrylamide, bis(acrylamide), agarose, o-phena-
troline (OP), and NaCN were from Merck KgaA (Darmstadt, Germany).
Dimethyl sulfate (DMS), KMnO4, diethyl pyrocarbonate (DEPC), KBr,
KHSO5, and thiourea were from Sigma. [g-
32P]-deoxyriboadenosine tri-
phosphate ([g-32P]dATP) was from MP Biomedicals, LLC (Irvine, CA).
Dimethyl sulfate (DMS) was from Sigma.
Platination reactions
The single-stranded oligonucleotides (the top strands of the duplexes shown in
Fig. 1 B) were reacted in stoichiometric amounts with transplatin. The plati-
nated oligonucleotides were repuriﬁed by ion-exchange fast protein liquid
chromatography (FPLC). It was veriﬁed by platinum FAAS and by the mea-
surements of the optical density that the modiﬁed oligonucleotides contained
one platinum atom. It was also veriﬁed using DMS footprinting of platinum on
DNA (14,26) that one platinum molecule was coordinated to two guanines at
their N7 position in the top strands of the duplexes shown in Fig. 1 B. The
platinated top strandswere allowed to anneal with unplatinated complementary
strands (the bottom strands shown in Fig. 1 B) in 0.2 M NaClO4. Other details
are in the text (vide infra) or have been described previously (14,27,28).
Rearrangement of intrastrand cross-links
of transplatin
The platinated single-stranded oligodeoxyribonucleotides (the top strands
of the 20-bp duplexes shown in Fig. 1 B) (20 mM) were allowed to anneal
with the unplatinated complementary (bottom) strands in 0.2MNaClO4, 5mM
Tris-HCl buffer (pH 7.5) and 0.1 mM EDTA at 20C for 30 min, and for 2 h
at 4C. Samples of these duplexes (2 mM) were further incubated at 37C in
the same medium; at various time intervals, aliquots were withdrawn and
analyzed by electrophoresis in 12% PAA/8M urea gel. The bases involved in
the interstrand CLs were determined byMaxam-Gilbert footprinting (14,22).
Digestion by o-phenanthroline-copper complex
and chemical modiﬁcations
o-Phenanthroline-copper complex (OP-Cu) digestions were carried out ac-
cording to the procedure described previously (29) with minor modiﬁcations
(30). Platinated and unplatinated oligonucleotides were 59-end labeled with
T4 polynucleotide kinase with the appropriate [g-32P]dNTP. After digestion
with OP-Cu, transplatin was removed after reaction of the DNA with the
probe by incubation with 0.2 M NaCN (pH 11) at 45C for 10 h in the dark.
FIGURE 1 (A) Structures of the platinum complexes. (B) Sequences of
the synthetic oligodeoxyribonucleotides used in this study with their
abbreviations. The top and bottom strands of each pair are designated top
and bottom, respectively, in the text. The bold letters in the top strands of the
duplexes indicate the location of the 1,3-intrastrand cross-link after modi-
ﬁcation of the oligodeoxyribonucleotides by transplatin in the way described
in the experimental section; the bold letters in the bottom strands of these
duplexes indicate the location of the sites that were involved in the inter-
strand cross-links after the linkage isomerization reaction was completed (see
the text).
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Modiﬁcations by KMnO4, DEPC, and KBr/KHSO5 were carried out as
described previously (27,31–33) at 4C. The duplex strands were 59-end
labeled with [g32P]ATP. In the case of the platinated oligonucleotides,
transplatin was removed after reaction of the DNA with the probe by incu-
bation with 0.2 M NaCN (pH 11) at 45C for 10 h in the dark.
Isothermal titration calorimetry
The standard isothermal titration calorimetry (ITC) buffer for these studies
contained 50 mM NaCl with 10 mM phosphate buffer (Na2HPO4/NaH2PO4
[pH 7.0]). Sufﬁcient quantities of ITC solutions were prepared to carry out a
set of titrations of the 50 mM solution of the bottom strands of the duplexes
TGTGT(15) or CGCGC(15) (for their sequences, see Fig. 1 B) into the 5 mM
solution of the top strand of nonmodiﬁed TGTGT(15) or CGCGC(15) or the
same duplexes containing a single, site-speciﬁc 1,3-GNG intrastrand CL of
transplatin at 4C. Molar extinction coefﬁcients for the single-stranded un-
modiﬁed or platinated oligonucleotides (related to the strands that were 15
nucleotides long) used in the ITC experiments were determined as described
in our previous articles (34–38), i.e., by phosphate analysis (39). Stock so-
lutions of the strands for ITC studies were prepared in the ITC buffer and
were exhaustively dialyzed against this buffer. It was veriﬁed that the en-
thalpies of ITC injections of each individual oligomer into buffer, of buffer
into buffer, and of excess oligomer into a solution of the duplex were all the
same as water into water injections, within error. From this data, it was
concluded that the effects of any solvent mismatching are negligible. Titra-
tions were carried out on a VP-ITC instrument (MicroCal LLC, North-
ampton, MA). For each titration, the top strand of the nonmodiﬁed
TGTGT(15) or CGCGC(15) duplex or the same duplex containing a single,
site-speciﬁc 1,3-GNG intrastrand CL of transplatin was loaded into a 1.4-ml
sample cell, and the complementary oligomer (bottom strand of the duplex
TGTGT(15) or CGCGC(15)) was loaded into the 300 mL injection syringe.
The stirring rate of the injection syringe was 400 rpm, and the samples were
equilibrated thermally before each titration until the baseline had leveled off
and the rms noise was,0.015 mcal3 s1. A typical titration consisted of 50
injections of 5 mL each, with 3 min between injections. The data from in-
dividual titrations were analyzed by using the Origin 5.0 software package
(Origin, Northampton, MA) to extract the relevant thermodynamic param-
eters [the enthalpy change (DH), the entropy change (DS), the stoichiometry
(n), and the equilibrium constant (K) for strand association].
Replication mapping of the 1,3-GNG
intrastrand cross-links
Replication with Sequenase 2 and electrophoretic analysis of the products of
the DNA polymerization reaction were carried out according to the protocols
recommended by Amersham, Pharmacia and in Burstyn et al. (40) and Intini
et al. (41). The (AflIII/EcoRI) restriction fragment (410 bp) from plasmid
pUC19, which had been used as a template for Sequenase 2, was modiﬁed
with transplatin in 10 mM NaClO4 at 37C for 24 h in the dark. The level of
platination of DNA corresponded to rb ¼ 0.001 (rb is deﬁned as the number
of platinum atoms coordinated per nucleotide residue in DNA). Other details
are in the text.
Other physical methods
Absorption spectra were measured with a Varian Cary 4000 UV-VIS spec-
trophotometer equipped with a thermoelectrically controlled cell holder and
quartz cells with the pathlength of 1 cm. Puriﬁcation of oligonucleotides with
the aid of HPLC was carried out on a Waters HPLC system consisting of
Waters 262 Pump, Waters 2487 UV detector, and Waters 600S Controller
withMonoQHR 5/5 column. The FAASmeasurements were carried out on a
Varian AA240Z Zeeman atomic absorption spectrometer equipped with a
GTA 120 graphite tube atomizer. For FAAS analyses, DNAwas dissolved in
0.1 M HCl. The gels were visualized by using a BAS 2500 FUJIFILM bio-
imaging analyzer, and the radioactivity associated with each band was
quantitated with the AIDA image analyzer software (Raytest, Germany).
RESULTS
Stability of the 1,3-GNG intrastrand cross-links
of transplatin
Previous studies (17,42) have shown that the 1,3-GNG in-
trastrand CL of transplatin is stable within single-stranded
DNA under physiological conditions. It has also been shown
(17,42) that within double-helical DNA, the stability of the
CL formed by transplatin in some selected sequence contexts
is reduced markedly and is even notably smaller than that of
the interstrand CLs (preferentially formed by this platinum
compound between guanine and complementary cytosine
residues (14)). Consequently, the pairing of single-stranded
DNA containing a 1,3-GNG intrastrand CL of transplatin in
these selected sequence contexts with their complementary
DNA strands results in a rearrangement of these intrastrand
adducts into interstrand CLs (17,42).
The stability of 1,3-GNG intrastrand CLs of transplatin
was investigated using 20-mer oligodeoxyribonucleotides
(the top strands of the duplexes shown in Fig. 1 B) that were
radioactively labeled at their 59-ends and platinated so that
they contained single and central, site-speciﬁc 1,3-GTG,
GGG, or GCG intrastrand CL. The sequences of these du-
plexes (Fig. 2) were chosen to substantially complement the
spectrum of sequence contexts in which these CLs were
formed and used in the previous studies (17,42) of the stabil-
ity of 1,3-intrastrand CLs of transplatin. The single-stranded
oligonucleotides containing this CL or the corresponding
duplexes (Fig. 2) were incubated in 0.2 M NaClO4 at 37C.
At various time intervals, aliquots were withdrawn and an-
alyzed by gel electrophoresis under denaturing conditions
(shown for the duplexes TGTGT and TGCGC in Fig. 3, A
and B, respectively). The 1,3-GNG intrastrand adducts of
transplatin in all single-stranded oligonucleotides (the top
strands of the duplexes shown in Fig. 1 B) were inert over a
long period of time (.5 days) (not shown). It was veriﬁed by
DMS footprinting that no rearrangement of the 1,3-intra-
strand CL occurred within this period. In contrast, the adduct
formed by transplatin after pairing the platinated single-
stranded oligonucleotides with their complementary strands
was labile, consistent with the previous results (17,42). As a
function of time, the radioactivity associated with the band
corresponding to the 1,3-intrastrand CL decreased with a
concomitant increase of the radioactivity associated with the
new, more slowly migrating species (shown for the duplexes
TGTGT and TGCGC containing the 1,3-GTG intrastrand
CLs of transplatin in Fig. 2 A). This new band migrated at
approximately the same rate as the 20-bp duplex TGTGT
containing a single interstrand CL (this cross-link resulted
from the reaction between the oligonucleotide and transplatin
carried out as described (14)). No other bands were detected.
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Similar results were obtained at higher concentrations of the
platinated duplex, which excluded an interduplex reaction.
This result was interpreted tomean that the 1,3-intrastrand CL
was transformed into an interstrand CL (17,42). After 24 h of
incubation of the duplexes TGTGT and TGGGT containing a
1,3-intrastrand CL of transplatin, 70% and 54% of the 1,3-
intrastrand CLs were transformed into the interstrand CLs
(Table 1 and shown for the CL in the TGTGT duplex in Fig.
2B). On the other hand, the yield of this rearrangement reaction
involving the formation of a 1,3-intrastrand CL of transplatin
in the sequences TGCGT, CGCGC, AGCGA, CGCGT,
TGCGT was radically lower in the range of only 7%–26%
(Table 1 and shown for the duplex TGCGC in Fig. 2 B).
The bases in the interstrand CLs resulting from the re-
arrangement of the 1,3-intrastrand CLs were identiﬁed from
Maxam-Gilbert footprinting in the same way as described in
previous articles (17,42) (not shown). The results indicated
that the interstrand CLs of transplatin in all duplexes tested in
this work were always formed between the platinated 59 G of
the 1,3-GNG intrastrand CL and the complementary C.
Chemical probing of conformational distortions
We tested an eventuality that an important factor contributing
to differences in the rate of rearrangement of intrastrand CLs
formed by transplatin in various sequence contexts into inter-
strand adducts is the character and extent of conformational
distortion and resulting local destabilization of double-stranded
DNA. We characterized conformational alterations induced in
DNA by intrastrand CLs of transplatin in the 20-bp duplexes
TGTGT or CGCGC containing a central, site-speciﬁc CL
treating these duplexes with several chemical agents that are
used as tools for monitoring the existence of conformations
other than canonical B-DNA. The duplexes TGTGT and
CGCGCwere chosen to represent groups of duplexes inwhich
the yield of the linkage isomerization reaction is high and very
low, respectively (Table 1). In addition, to minimize the re-
arrangement of intrastrandCLsof transplatin to interstrandCLs
during reactions of intrastrand crosslinked duplexes with
chemical probes, which could obscure analysis focused on
intrastrand CLs, the intrastrand crosslinked duplexeswere kept
at 4C for 12 h; at this temperature rearrangement of the 1,3-
GNG intrastrand CLs is reduced markedly. It was veriﬁed by
gel electrophoresis (vide supra) that the 1,3-GTG intrastrand
CL formed in the duplexes TGTGT and CGCGCwas stable at
4C so that only 1.3% and 0.7% of intrastrand crosslinked
duplexes TGTGT and CGCGC, respectively, were trans-
formed into interstrand crosslinked within 12 hr (not shown).
Reactions with chemical nuclease or chemical probes were
carried out at 4C, but the times of these reactions were only
5–30 min (see Materials and Methods). Therefore, it was also
veriﬁed by gel electrophoresis that only a negligible fraction
(,1%) of duplexes containing a 1,3-GTG intrastrand CL
formed in the duplexes TGTGT or CGCGC rearranged to in-
terstrand crosslinked duplexes within 30 min (not shown).
OP-Cu is a chemical nuclease that nicks nucleic acids by
oxidation attack on the sugar moiety (43,44). The cleavage
efﬁciency of OP-Cu is dependent on the secondary structure of
DNA. A comparison of the cleavage patterns of unplatinated
TGTGT duplex and those modiﬁed with a 1,3-intrastrand CL
of transplatin shows a markedly lower reactivity of the central
nucleotide sequence containing the CL (Fig. 3 A). In contrast,
the cleavage pattern of unplatinated CGCGC duplex and of
those modiﬁed with a 1,3-intrastrand CL of transplatin also
FIGURE 2 Rearrangement of the 1,3-intrastrand cross-
links formed by transplatin in the duplexes TGTGT and
TGCGC. The top strands of these duplexes were modiﬁed
so that they contained a single, site-speciﬁc 1,3-GNG
intrastrand cross-link. These platinated single-stranded
oligodeoxyribonucleotides (20 mM) were allowed to anneal
with the unplatinated complementary (bottom) strands in
0.2 M NaClO4, 5 mM Tris-HCl buffer (pH 7.5), and 0.1
mM EDTA at 20C for 30 min, and for 2 h at 4C. Samples
of these duplexes (2 mM) were further incubated at 37C in
the same medium; at various time intervals, the aliquots
were withdrawn and analyzed by electrophoresis in 12%
PAA/8 M urea gel. (A) Autoradiograms of the gels of the
duplex TGTGT (left) and TGCGC (right), both modiﬁed by
transplatin radioactively labeled at the 59-end of its top
strand. Incubation times in minutes are indicated under each
lane. Lane 1 refers to the 59-end labeled single-stranded top
(platinated) strand. (B) Plot of the percentages of 1,3-
intrastrand CL of transplatin in TGTGT (s) or TGCGC
(:) versus time. These percentages were calculated from
the ratio of the radioactivity in each lane in panel A
associated with the band corresponding to the lower bands
in panel A to the sum of the radioactivities associated with
both bands (multiplied by 100). For other details, see the
text.
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shows an altered reactivity of the central nucleotide sequence
containing the CL (Fig. 3 B), but different from that seen for
the central nucleotide sequence containing the CL in the du-
plex TGTGT. We interpret the results obtained with OP-Cu
nuclease to mean that the geometry of the double helix is al-
tered over several base pairs around the 1,3-intrastrand CL in
both sequence contexts, but differently.
The other agents used as chemical probes of DNA con-
formation also include KMnO4, bromine, or DEPC as probes
for thymine, cytosine, and adenine/guanine residues, re-
spectively (27,31–33,45). These chemical probes react, un-
der the conditions used, with base residues in single-stranded
DNA and distorted double-stranded DNA, but not with the
base residues in intact, double-stranded DNA (27,31–33,45).
For this analysis, we used exactly the samemethodology as in
our recent studies dealing with DNA adducts of various an-
titumor platinum drugs. Thus, the details of this experiment
can be found in those articles (27,46), and representative gels
showing piperidine-induced speciﬁc strand cleavage at
KMnO4-modiﬁed, KBr/KHSO5-modiﬁed, and DEPC-mod-
iﬁed bases in the TGTGT and CGCGC duplexes unplatinated
or containing a single 1,3-GNG intrastrand CL of transplatin
are shown in the Supplementary Material, Fig. S1.
The results are schematically summarized in Fig. 4. The
pattern and degree of reactivity toward the chemical probes
were different for the 1,3-GNG intrastrand CLs formed by
transplatin in the sequences TGTGT and CGCGC. The extent
of the distortion was markedly larger in the TGTGT sequence
than in the CGCGC sequence (Fig. 4), indicating the se-
quence-dependent character of the conformational distortion
induced by the 1,3-GNG intrastrand CL of transplatin.
Isothermal titration calorimetry
Calorimetric technique was used to characterize the inﬂuence
of the 1,3-GNG intrastrand CLs of transplatin on the thermal
FIGURE 3 Quantitation of Op-Cu digestion of TGTGT (A), CGCGC (B)
duplexes, and their analogs containing a single, site-speciﬁc 1,3-GNG
intrastrand cross-link. The autoradiograms (not shown) were quantitated
by microdensitometry. The black bars represent digestion of the unplatinated
duplexes, and the light bars represent digestions of the platinated duplexes.
The heights of the bars are proportional to the band intensities on the
autoradiograms.
TABLE 1 Rearrangement of single, site-speciﬁc 1,3-GNG







at 37C (%) t50% (h)y Reference
TGAGT 91 6 (42)
TGTGT 70 12 (42) and this work
59-CGTGT .50 6 (42)
59-TGTGC .50 18 (42)
59-GGTGT .50 4 (17)
AGAGA .50 1.6 (17)
TGAGT .50 4.8z (17)
TGGGT 43 .24 this work
TGCGT 29 .24 this work
CGCGC 26 .24 this work
AGCGA 18 .24 this work
59-CGCGT 14 .24 this work
TGCGC 7 .24 this work
The platinated duplexes (2 mM) were incubated in a medium of 0.2 M
NaClO4, 5 mM Tris-HCl, pH 7.5 at 37C.
*The central nucleotide sequence of the top strand of the 20-bp duplex at
which the 1,3-GNG intrastrand cross-link of transplatin was formed. Gs in
bold represent the platinated sites in the intrastrand cross-link.
yThe time at which the rearrangement reached 50%.
zThis value was obtained for the rearrangement reaction at 40C.
FIGURE 4 Summary of the reactivity of chemical probes with the duplexes
TGTGT and CGCGC containing a 1,3-GNG intrastrand cross-link of trans-
platin. Solid, half-solid, and open circles designate strong, medium, or weak
reactivity, respectively.
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stability and energetics of the site-speciﬁcally platinated 15-
bp DNA duplexes containing the central sequences TGTGT
and CGCGC (duplexes TGTGT(15) and CGCGC(15), for
their sequence, see Fig. 1 B). Such thermodynamic data can
show how the platinum CL inﬂuences duplex stability, a
property that has been shown to play a signiﬁcant role in
cellular processes, such as recognition of DNA damage by
DNA-binding proteins and repair of this damage, i.e., the
processes that may modulate potency of antitumor drugs
including metal-based cytostatics. Recently, differential
scanning calorimetry (DSC) was used to characterize the
inﬂuence of different CLs of platinum antitumor drugs on the
thermal stability and energetics of 15–20-bp DNA duplexes
site-speciﬁcally modiﬁed by these drugs (34–36,47,48). We
decided to expand these studies to oligodeoxyribonucleotide
duplexes containing unique 1,3-GNG intrastrand CLs formed
by transplatin in the TGTGT and CGCGC sequences. DSC
makes it possible to measure excess heat capacity versus
temperature proﬁles for the thermally induced transitions of
nonmodiﬁed DNA duplexes and the duplexes containing a
unique adduct of the metal-based drug. Such thermograms
are usually recorded with a heating rate of 60C/h and after
reaching the maximum temperature of 95C the samples are
cooled at the same rate to the starting temperature of 25C
(34,47–49). This implies that the duplexes containing the
unique adduct are exposed to higher temperatures for a rel-
atively long period. Hence, DSC does not seem to be suitable
for analysis of the duplexes containing 1,3-GNG intrastrand
CLs of transplatin since higher temperatures may facilitate
rearrangement of this CL to interstrand CL; a more prominent
fraction of interstrand crosslinked duplexes in a sample of
intrastrand crosslinked duplexes would obscure analysis of
the intrastrand adducts. A suitable alternative is ITC, which
makes it possible to study the thermodynamic parameters of
the duplex formation from its two complementary single
strands over a range of temperatures including low temper-
atures, such as 4C, at which the stability of the 1,3-GNG
intrastrand CLs is expected to be markedly enhanced. It was
veriﬁed by gel electrophoresis (vide supra) that the 1,3-GTG
intrastrand CL formed in the duplex TGTGT(15) was stable
at 4C, so that only,1% of intrastrand crosslinked duplexes
were transformed into interstrand crosslinked (not shown).
Fig. 5 shows the ITC proﬁles of duplex formation from the
nonmodiﬁed bottom strand of the duplexes TGTGT(15) and
CGCGC(15) titrated into complementary nonmodiﬁed top
strands, or into the same strands containing a single 1,3-GNG
intrastrand CL of transplatin at 4C. It was veriﬁed that the
melting temperature of the duplexes was signiﬁcantly higher
than this temperature and that the 1,3-intrastrand CLs of
transplatin formed in both 15-bp duplexes or in their single-
stranded top strands were stable for .12 h. The ITC proﬁles
were analyzed as described in Materials and Methods to
obtain the results listed in Table 2. All thermodynamic pa-
rameters discussed in this work refer to the duplex formation
process. Differences in the dissociation thermodynamics due
to the presence of the adduct are presented as ‘‘DD’’ pa-
rameters. These parameters are computed by subtracting the
appropriate value measured for the control, unmodiﬁed du-
plex from the value measured for the duplex containing a
single, site-speciﬁc intrastrand platinum CL.
Inspection of these thermodynamic parameters shows that
the exothermic formation of a single 1,3-intrastrand adduct in
the duplexes TGTGT(15) or CGCGC(15) by transplatin
resulted in a large decrease in the change in enthalpy of du-
plex formation by 17.0 and 7.4 kcal/mol, respectively. In
other words, the 1,3-GNG intrastrand CL of transplatin en-
FIGURE 5 Isothermal titration calorimetry. ITC binding
isotherms for the association of the top strand of the 15 bp
TGTGT(15) (A) and CGCGC(15) (B) duplexes containing
a single, site-speciﬁc 1,3-GNG intrastrand cross-link of trans-
platin with the complementary (nonmodiﬁed) strand (bot-
tom strands of the duplexes TGTGT(15) and CGCGC(15),
respectively) at 4C in 10 mM phosphate buffer (pH 7.0)
containing 50 mM NaCl. The upper panels show total heat
released on injecting 5 mL aliquots of the 50 mM bottom
strand into a 1.4 ml reaction cell containing the 5 mM top
strand. The lower panels show the resultant binding iso-
therm (solid squares) obtained by integrating the peak areas
of each injection. The continuous line represents the non-
linear least squares ﬁt of the afﬁnity (K), enthalpy (DH), and
stoichiometry (n) to a single-site binding model. For other
details, see the text.
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thalpically destabilizes the duplex relative to its nonmodiﬁed
counterpart. In addition, the formation of a 1,3-GNG intra-
strand CL by transplatin in both sequence contexts resulted in
a substantial increase in the entropy of the duplexes TGTGT(15)
or CGCGC(15) of 49 or 20 cal/Kmol (TDDS ¼ 13.6 and 5.5
kcal/mol at 4C), respectively. In other words, the 1,3-GNG
intrastrand CL of transplatin increases the entropy of the
platinated duplexes and in this way entropically stabilizes the
duplexes. Thus, the 17.0 or 7.4 kcal/mol enthalpic destabi-
lization of the TGTGT(15) or CGCGC(15) duplexes due to
the 1,3-GNG intrastrand CL of transplatin is partially, but not
completely, compensated by the entropic stabilization of the
duplexes induced by this adduct of 13.8 or 5.5 kcal/mol at
4C, respectively. The net result of these enthalpic and en-
tropic effects is that the formation of a 1,3-GNG intrastrand
CL with the duplexes TGTGT(15) or CGCGC(15) at 4C
induces a decrease in duplex thermodynamic stability
(DDG4C) of 3.2 or 1.9 kcal/mol, respectively, with this
destabilization being enthalpic in origin. In this respect, the
1,3-GNG intrastrand CL formed by transplatin in the TGTGT
sequence thermodynamically destabilized DNA consider-
ably more than that formed in the CGCGC sequence.
Replication mapping of the 1,3-GNG intrastrand
cross-links in the 410-bp DNA fragment
Further investigations were aimed at ﬁnding the sites in natural
DNA in which intrastrand CLs were formed during the reaction
with transplatin. Previous work has shown that the in vitro DNA
synthesis byDNApolymerases on aDNA templatemodiﬁed by
various platinum complexes is terminated at the level of the
adducts (50–52). A similar approach was used in this work.
The primer extension footprinting assay was used to de-
termine the sites of intrastrand CLs of transplatin, their se-
quence selectivity and stability. The AflIII/EcoRI fragment of
pUC19 plasmid (410-bp with a random natural nucleotide
sequence) was incubated with transplatin for 24 h at 37C; the
level of the modiﬁcation was relatively low and corresponded
to rb ¼ 0.001. To determine the location of the intrastrand
CLs,mapping analyseswere carried out using two types of the
410-bp fragments modiﬁed by transplatin. One type of frag-
ment was globally modiﬁed by transplatin and was used
without any further treatment, i.e., contained all types of DNA
adducts formed by transplatin. The other type contained ex-
clusively intrastrand CLs [the interstrand crosslinked frag-
ments were removed from the sample globally modiﬁed by
transplatin by separation on a denaturing agarose gel; mono-
functional adducts were removed from fragments containing
no interstrand CL by reaction with thiourea (14–16)].
After alkaline denaturation, the DNA samples were primed
with 20-mer primer (Fig. 1 B) and new DNAwas synthesized
by Sequenase 2 in the presence of [a-32P]dATP and unla-
beled dNTPs. The products of DNA polymerization were
separated by electrophoresis on a 6% polyacrylamide/8 M
urea denaturing gel in parallel to a sequence ladder obtained
using an untreated control DNA.
The strong and medium intensity bands observed speciﬁ-
cally for the template containing exclusively intrastrand CLs
(Fig. 6 A, lane Intra CLs) were taken to indicate the sites of
preferential formation of the intrastrand CLs of transplatin.
Importantly, they all occurred at or in immediate proximity to
the sequences, such as GGG or GCG (positions 612–614,
653–657, 665–667, 672–674, 681–683 (Fig. 6 B)), i.e., at the
sequences in which the yield of the rearrangement of intra-
strand CLs of transplatin into interstrand CLs was low (Table
1). Importantly, no bands were observed at the sequences,
such as GTG or GAG (positions 623–625, 660–664), in
which the yield of the rearrangement of intrastrand CLs of
transplatin into interstrand CLs was relatively high (Table 1).
On the other hand, many additional strong or medium in-
tensity bands were observed for the template containing all
types of transplatin adducts (i.e., besides intrastrand also
interstrand CLs and monofunctional adducts) indicating
small sequence selectivity of DNA binding of transplatin (G
and C stop sites) (Fig. 6 A, lane All adducts, and B) in accord
with the results published previously (14).
DISCUSSION
Clinically ineffective transplatin is often used in studies in-
vestigating the structure-pharmacological activity relationship
TABLE 2 Calorimetrically-derived thermodynamic parameters for the formation of the 15-bp duplexes nonmodiﬁed or containing
a single, site-speciﬁc 1,3-GNG intrastrand cross-link of transplatin at 4C
DHy DSy DG4C
y Kz
Duplex* kcal/mol duplex cal/Kmol duplex kcal/mol duplex M1 nz
TGTGT(15) 64.9 193 11.5 8.57 3 108 1.07
TGTGT(15)  transPt 47.9 (17) 144 (49) 8.0 (3.5) 3 3 106 1.01
CGCGC(15) 55.4 165 9.7 5.7 3 107 1.09
CGCGC(15)  transPt 48.0 (7.4) 145 (20) 7.8 (1.9) 1.5 3 107 1.01
The DH and DS values are averages derived from three independent experiments. The experimental uncertainties of the parameters are as follows: DH (2%),
DS (3%), DG4 (3%). ‘‘DD’’ parameters are in parentheses (these parameters are computed by subtracting the appropriate value measured for the control,
unmodiﬁed duplex from the value measured for the duplex containing a single, site-speciﬁc transplatin adduct).
*G’s in bold represent platinated guanine residues.
yDH, DS, and DG4 denote, respectively, the enthalpy, entropy, and free energy (at 4C) of duplex formation.
zK and n denote, respectively, the association constant and binding stoichiometry for strand association.
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ofplatinumcompounds (4). In addition, a numberof transplatin
analogs exhibit antitumor effects comparable to cisplatin or
even promising toxic effects in several cisplatin resistant tumor
cell lines (6,53). Also importantly, transplatin-modiﬁed oli-
gonucleotides have been shown to be effective modulators of
gene expression (19,20,54). These facts along with the gener-
ally accepted view that DNA is the major pharmacological
target of platinum antitumor complexes are impetus for the
studies of interactions between transplatin and DNA.
Bifunctional platinum compounds, such as transplatin,
cisplatin and their analogs, form on DNA various types of
CLs. These CLs are formed in a two-step process (55). In the
ﬁrst step, the monofunctional adducts are formed preferen-
tially at guanine residues that subsequently close to the CLs.
Several studies (17,19,56) have concluded that the major
bifunctional adducts formed by transplatin in double-helical
DNA are interstrand CLs and that intrastrand CLs are not
formed. It has been proposed (17,56) that stable intrastrand
CLs (1,3-GNG intrastrand CLs) are only formed in the re-
action between single-stranded DNA and transplatin and that
these intrastrand CLs rearrange into interstrand CLs as soon
as the platinated single-stranded DNA is paired with its
complementary strand. The conclusion that transplatin forms
in double-helical DNA no intrastrand CLs was drawn on the
basis of the results showing instability of the 1,3-intrastrand
CLs formed by transplatin only in a relatively small number
of selected sequence contexts (17,56,57). On the other hand,
earlier work (14–16) has indicated that transplatin forms di-
rectly in double-helical DNA beside monofunctional adducts
and a relatively small amount of interstrand CLs (;12%) also
a considerable amount of 1,3-GNG intrastrand CLs.
We show in this study that transplatin forms in double-
helical DNA 1,3-GNG intrastrand CLs, but their stability
depends on the sequence context (Table 1). We conﬁrm that
in the nucleotide sequences tested in the previous work
(17,56,57) the 1,3-GNG intrastrand CLs of transplatin readily
rearrange in double-helical DNA into interstrand CLs. On the
other hand, we also show that in a number of other sequences
these CLs are relatively stable. This conclusion is drawn on
the basis of the results obtained not only with short synthetic
oligodeoxyribonucleotide duplexes (Fig. 2, Table 1), but also
with natural DNA with a random sequence (Fig. 6).
We also tested the hypothesis that the sequence-dependent
stability of 1,3-GNG intrastrand CLs of transplatin in double-
FIGURE 6 (A) Autoradiogram of a 6% polyacrylamide/
8 M urea sequencing gel showing inhibition of DNA
synthesis by Sequenase 2 on transplatin-modiﬁed (Afl III/
EcoRI) fragments 410 bp long. After reaction with trans-
platin at 37C in 10 mM NaClO4 for 24 h, rb ¼ 0.001, one
half of the sample was left so that it contained all types of
DNA adducts of transplatin. The fragments contained in the
other half were further separated by gel electrophoresis, so
that all interstrand cross-linked fragments were removed
and the fraction of fragments containing no interstrand
cross-links was still treated with thiourea to remove
monofunctional adducts. Thus, the other half of the frag-
ments treated in this way contained exclusively intrastrand
cross-links (for other details, see the text). Lanes: noPt,
relative to the unplatinated template; All adducts, relative to
the DNA globally modiﬁed by transplatin containing all
types of transplatin adducts; IntraCLs, relative to the DNA
containing exclusively intrastrand cross-links; A, T, G, and
C are relative to chain terminated marker DNAs. (B)
Schematic diagram showing a portion of the sequence
used to monitor inhibition of DNA synthesis by transplatin.
The arrow indicates the start site of Sequenase 2. d and D,
stop signals from panel A. d, all types of adducts; D,
intrastrand cross-links. Numbers correspond to nucleotide
numbering on the pUC19 nucleotide sequence map.
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helical DNA and their propensity to rearrange into interstrand
CLs is dependent on the extent of local conformational dis-
tortion and consequent destabilization of double-helical
DNA by this intrastrand adduct. In other words, we examined
whether a more extensive local destabilization of double-
helical DNA due to the 1,3-GNG intrastrand CL may facil-
itate its rearrangement into interstrand CLs. An analysis of
conformational distortions induced in DNA by 1,3-GNG
intrastrand CLs of transplatin carried out in this study showed
substantial differences in the character of these distortions if
the CL was formed in the TGTGT or CGCGC sequence
(Figs. 3 and 4), i.e., in the sequences in which stability of the
intrastrand CLs in double-helical DNA is low or high, re-
spectively (Table 1). The analysis by chemical probes of
DNA conformation showed (Fig. 4) that the distortion in-
duced in the sequence TGTGT extended over at least 7 bp,
whereas the distortion induced in the sequence CGCGC was
less extensive and markedly less pronounced.
Consistent with this observation were the results of the ITC
analysis (Fig. 5 and Table 2). The association constants, K, for
the formation of duplexes TGTGT(15) and CGCGC(15) con-
taining 1,3-GNG intrastrand CLs of transplatin were 286 or 4
times lower, respectively, than theK value for the formation of
the control (nonmodiﬁed) duplexes (Table 2). Hence, the 1,3-
intrastrand CLs formed in both TGTGT or CGCGC sequences
thermodynamically destabilizedDNA,with this destabilization
being enthalpic in origin. Importantly, the formation of the in-
terstrand CL of transplatin induces no marked changes not
only in enthalpy, but also in transition entropy (38). Thus, in
contrast to intrastrand CLs, interstrand CLs of transplatin
structurally perturb DNA in a way that does not lead to the
pronounced thermodynamic destabilization consistent with
conformational analysis of the interstrand CL of transplatin
carried out by the methods of molecular biophysics (27).
Therefore, it seems reasonable to suggest that a driving force
behind the process involving rearrangement of the 1,3-GNG
intrastrand CLs formed by transplatin in double-helical DNA
to interstrand CLs is thermodynamic destabilization imposed
onDNA by the 1,3-GNG intrastrand CL formed by transplatin
in a respective nucleotide sequence context.
In aggregate, the 1,3-GTG intrastrand CL formed in the
TGTGT sequence destabilized DNA considerably more than
the CL formed in the CGCGC sequence, in which this CL
exhibits a markedly higher stability (Table 1). Hence, the
results of the ITC analysis are consistent with the view and
support the hypothesis that the reduced propensity of the 1,3-
GNG intrastrandCL of transplatin in the CGCGC sequence to
rearrange into an interstrand CL is associated with its mark-
edly lowered efﬁciency to destabilize thermodynamically
DNA in contrast to the CL formed in the TGTGT sequence.
The data in this study provide new information on DNA
interactions of clinically ineffective transplatin, which is
used frequently in studies of structure-pharmacological re-
lationship of platinum complexes as a counterpart of antitu-
mor cisplatin. In addition, this study has provided valuable
information for the design of new antitumor analogs of
transplatin. Notably, a number of new analogs of transplatin,
which we believe shows promising toxicity in various
tumor cell lines, form in double-helical DNA a large number
of stable intrastrand CLs. For instance, trans-[PtCl2
(NH3)(piperidine)], trans-[PtCl2(NH3)(piperazine)], trans-[PtCl2
(NH3)(4-hydroxymethylpyridine)], trans-[PtCl2(4-picoline)
(piperidine)], and trans-[PtCl2(4-picoline)(piperazine)] HCl
form in DNA after 24 h at 37C 60%–90% stable intrastrand
CLs (23–25). Thus, it cannot be excluded that the capability
of these transplatinum complexes to form in double-helical
DNA a relatively high number of stable intrastrand CLs
might be one of the factors signiﬁcantly contributing to the
activation of trans geometry in platinum coordination com-
plexes. This work suggests that an enhanced frequency of
intrastrand CLs yielded by these new transplatinum com-
plexes might be a consequence of the fact that intrastrand CLs
of these new analogs of transplatin thermodynamically de-
stabilize DNA in far less sequence contexts than inefﬁcient
parent transplatin. Another eventuality might be that inter-
strand CLs of these new transplatinum complexes distort and
consequently thermodynamically destabilize DNA markedly
more than the same adducts of parent transplatin, which
could also make the rearrangement of intrastrand CLs into
interstrand CLs difﬁcult. The work aimed at testing these
intriguing hypotheses, positive testing of which would ra-
tionalize the design of new antitumor drugs based on trans-
platin analogs, is in progress in our laboratory and the results
will be reported in further communication. Our ﬁndings may
also be useful for the design of transplatin-modiﬁed oligo-
nucleotides as modulators of gene expression emphasizing a
need to carefully design nucleotide sequence contexts in
these oligonucleotides for the platination.
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